S481
Clinical - Gynaecological
ESTRO 2026
chemotherapy. No grade 4–5 events were observed. Conclusion: Daily ITV-free oART pelvic radiotherapy is feasible and achieves consistent target coverage with reduced OAR exposure. Early results demonstrate low toxicity and good oncologic outcomes, supporting continued evaluation in larger prospective studies. References: Concin N, et al. ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025. Lancet Oncol 2025;26:e423–35.Harkenrider MM, et al. Radiation Therapy for Endometrial Cancer: An American Society for Radiation Oncology Clinical Practice Guideline. Pract Radiat Oncol 2023;13:41–65.Siegel RL, et al. Cancer statistics, 2024. CA Cancer J Clin 2024;74:12–49.Small WJ, et al. NRG Oncology/RTOG Consensus Guidelines for Delineation of Clinical Target Volume for Intensity Modulated Pelvic Radiation Therapy in Postoperative Treatment of Endometrial and Cervical Cancer: An Update. Int J Radiat Oncol Biol Phys 2021;109:413–24. Keywords: Endometrial, On-line Adaptive, Dosimetric analysis Digital Poster 4342 “Hidden Battles: Sexual Dysfunction and Quality of Life Challenges in Cervical Cancer Survivorship” ALTAF HOSSAIN 1 , Golam Zel Asmaul Husna 1 , Saiful Alam 1 , Nowshin Taslima Hossain 2 , Tasneem Hossain 1 , Saiful Huq 3 , A F M Kamal Uddin 4 1 Radiation Oncology, National Institute of Cancer Research and Hospital, Dhaka, Bangladesh. 2 Radiation Oncology, Ahsania Mission Cancer and General Hospital, Dhaka, Bangladesh. 3 Radiation Oncology, UPMC Hilman Cancer Center, Pittsburgh, USA. 4 Radiation Oncology, LabAid Cancer and Superspeciality Center, Dhaka, Bangladesh
Purpose/Objective: This study aimed to estimate the magnitude of female sexual dysfunction (FSD) among cervical cancer survivors, identify clinical and sociodemographic factors associated with FSD, and assess the relationship between sexual dysfunction and overall QOL. Material/Methods: A cross-sectional study was conducted among 217 cervical cancer survivors who had completed definitive treatment at the National Institute of Cancer Research and Hospital (NICRH). The sample size was calculated using a single-proportion formula with 95% confidence level, 5% margin of error, and p = 0.5, applying finite population correction for N = 400 and 10% non- response. Ethical approval was obtained from the NICRH IRB, and written informed consent was secured prior to data collection. Data were collected using validated Bangla versions of the Female Sexual Function Index (FSFI-6; Cronbach’s α = 0.887) and the Functional Assessment of Cancer Therapy– General (FACT-G; Cronbach’s α = 0.84). Mean FSI-6 and QOL score was calculated (Including the different domains). Multiple linear regression was performed to identify independent predictors of FSFI score and to adjust for potential confounders. Spearman’s
correlation was used to assess the relationship between FSFI and QOL. Results:
All participants experienced some degree of sexual dysfunction, with a mean FSFI score of 11.72 ± 2.85. In multivariate analysis, menopausal status, treatment modality, and disease stage were independently associated with FSFI score (Adjusted R ² = 0.604, p < 0.001). Postmenopausal women had higher FSFI scores ( β = 1.24, 95% CI 0.65–1.83, p < 0.001), whereas advanced stages (Stage III: β = –2.12; Stage IV: β = –3.63, p < 0.01) and more intensive treatment modalities ( β = – 1.67 to –5.63, p ≤ 0.003) were associated with poorer sexual function. Age, education, religion, histology, and treatment duration
Made with FlippingBook - Share PDF online